PRODUCTS & INNOVATION
ABBOTT POSTS STRONG 2019 RESULTS
Another highly successful year of performance gives us momentum for the year ahead.
Jan 22 2020
We closed out 2019 on top once again!
Thanks to strong performances by all four of our businesses, impressive organic growth and more than 25 significant product approvals and developments, Abbott had another successful year.
Contributing to this success was our strong fourth-quarter results with organic sales* growth of 8.5% (7.1% reported), led by double-digit growth in several businesses — Medical Devices, Established Pharmaceuticals and Core Laboratory.
As we look ahead to 2020, we expect another standout year. We announced full-year adjusted earnings-per-share guidance of $3.55 to $3.65 ($2.35 to $2.45 on a GAAP basis), reflecting double-digit growth at the midpoint and organic sales growth of 7.0 to 8.0%.†
Our sound strategy fuels this consistent, quarter-after-quarter growth. Key to this strategy is the deliberate way we’ve built the company, and our commitment to important healthcare trends.
Our Portfolio Is Delivering Top-Line Growth
Across our businesses, our life-changing innovations are driving the future of healthcare, including:
For full financials, you can read our press release, or take a look at some additional materials below:
Abbott's Chairman and CEO Miles D. White shared his views on fourth-quarter performance:
Learn more about Abbott's fourth-quarter 2019 results:
Download a summary of Abbott’s earnings highlights here.
For more information on Abbott's earnings results, see the news release.
*Organic sales growth excludes the results for a non-core business within U.S. Adult Nutrition during the first nine months of 2018 as this business was discontinued during the third quarter 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 22, 2020, available at www.abbottinvestor.com.
† Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.
‡ Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
*Editor's note: After a remarkable 21-year tenure, Miles White stepped down as Abbott's CEO on March 31, 2020. At that time, Robert Ford became the CEO of Abbott. Mr. White remains Abbott's Executive Chairman, serving on Abbott's Board of Directors.
Freestyle Libre 2: Next-Gen CGM is Here
FreeStyle Libre System Poised for Broader Reach
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.